Health Care Archives - Page 32 of 478

2 minute read

Eli Lilly’s Weight-Loss Drug Still Going Strong, Boosts Annual Forecast

April 30, 9:41 AM

"Eli Lilly & Co's Q1 2024: Revenue hits $8.8 billion, up 26% Y/Y, driven by volume & higher prices. Strong demand for key drugs like Mounjaro & Verzenio. EPS beats at $2.58. FY24 guidance raised to $42.4 billion-$43.6 billion, citing robust performance.

LLY

2 minute read

AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown

By Vandana Singh

April 29, 2:38 PM

Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and potential ramifications.

AZN

2 minute read

Why Is Alzheimer’s-Focused Annovis Bio Stock Nosediving On Monday?

By Vandana Singh

April 29, 1:53 PM

Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in treatment groups.

ANVS

2 minute read

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

By Vandana Singh

April 29, 12:36 PM

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.

MOR

1 minute read

Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?

By Vandana Singh

April 29, 12:17 PM

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including QINLOCK. Acquisition expected to close Q3 2024.

DCPH

2 minute read

FDA Approves X4 Pharmaceuticals’ Mavorixafor As First Therapy For Rare Immunodeficiency Disorder

By Vandana Singh

April 29, 12:10 PM

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

XFOR

2 minute read

Johnson & Johnson-Partnered Addex Therapeutics’ Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks

By Vandana Singh

April 29, 10:53 AM

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.

ADXN

2 minute read

Double Good News For AstraZeneca’s Breast Cancer Drugs

By Vandana Singh

April 29, 9:25 AM

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

AZN

2 minute read

Philips Reaches $1.1B Settlement On US Sleep Apnea Devices’ Claims, Backs Annual Guidance

By Vandana Singh

April 29, 8:44 AM

Philips settles $1.1 billion in Respironics ventilator recall lawsuit. Updates on Philips' Q1 performance and 2024 guidance. PHG shares surge 36.9% in premarket trading.

PHG

2 minute read

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle

By Vandana Singh

Today, 2:45 PM

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent infringement in mRNA technology.

BNTX